Over a month after iCare’s parent company— Revenio Group Corporation—first announced plans to acquire Visionix, the companies have officially combined their ophthalmic medical device and imaging portfolios.
Can you refresh me on this merger?
As we reported last month, Revenio shared plans to acquire Visionix as part of a strategic partnership bringing together the two companies’ complementary businesses.
- More specifically: Revenio purchased Visionix's entire capital share from its parent company, the French LT International SAS.
And since that announcement: The companies have continued to work through an integration process of their business—all while ensuring their respective customer contacts and support channels remain unchanged (and will continue as such).
Tell me the basics of Visionix.
While the ophthalmic medical equipment manufacturer is headquartered in France, its U.S. arm (Visionix USA) operates out of Illinois.
Its product portfolio: Includes an array of integrated technologies for eyecare professionals (ECPs) in the optometry, ophthalmology, and optical fields.
Talk more about these technologies.
Among them: Autorefractors; autolensmeters / lens analyzers; clinical pre-test / vision screening instruments; optical coherence tomographers (OCT) / OCT angiographers (OCTA); fundus cameras, lens edgers; refraction equipment; and slit lamps.
And a few popular brand names worth mentioning:
- Briot line of in-office lens edging and finish equipment
- Optuvue line of OCT / OCTA instruments
- Visionix line of diagnostic, screening, and wave-front-based instruments
- Weco line of industrial and retail optical lens finishing, edging, drilling, and lab equipment
Plus, Visionix previously partnered with 20/20NOW to launch a tele-optometry program across the United States.
So how does iCare complement this, exactly?
Operating under Revenio, a Finnish global healthcare technology company, the advanced healthcare technology company boasts a product line of medical devices for screening and diagnosing ocular diseases.
Included in this device portfolio: fundus perimeters, microperimeters, retinal imaging, rebound tonometers, and other solutions. See here for more
… and when put together?
The companies noted the establishment of a broader and more comprehensive portfolio that spans "diagnostics, imaging, refraction, OCT, software, and other (artificial intelligence [AI]-enabled) connected workflow solutions.”
So what can customers and partners expect from this expanded offering?
In essence: increased access.
As Revenio CEO Jouni Toijala stated: “We are creating a stronger company with broader capabilities, greater scale, and a highly comprehensive offering for eyecare professionals globally.”